Feltgen, Nicolas

[["dc.bibliographiccitation.firstpage","3097"],["dc.bibliographiccitation.issue","20"],["dc.bibliographiccitation.journal","FEBS letters"],["dc.bibliographiccitation.lastpage","3102"],["dc.bibliographiccitation.volume","582"],["dc.contributor.author","Stahl, A."],["dc.contributor.author","Paschek, L."],["dc.contributor.author","Martin, G."],["dc.contributor.author","Gross, N. J."],["dc.contributor.author","Feltgen, N."],["dc.contributor.author","Hansen, L. L."],["dc.contributor.author","Agostini, H. T."],["dc.date.accessioned","2019-07-09T11:52:59Z"],["dc.date.available","2019-07-09T11:52:59Z"],["dc.date.issued","2008"],["dc.description.abstract","Anti-VEGF treatment has become accepted first-line treatment for choroidal neovascularisation (CNV) in age-related macular degeneration. However, VEGF-inhibition does not always lead to sustained CNV-reduction. In this study, the effect of rapamycin was superior to VEGF-inhibition in a co-culture assay of endothelial cells (ECs) and retinal pigment epithelium (RPE). Rapamycin reduced EC sprouting in groups that did not respond to anti-VEGF treatment. Rapamycin did not induce EC apoptosis, but reduced both VEGF-production in RPE and the responsiveness of ECs to stimulation. Rapamycin might therefore be a therapeutic option for CNV patients that do not respond sufficiently to the established anti-VEGF treatments."],["dc.identifier.doi","10.1016/j.febslet.2008.08.005"],["dc.identifier.pmid","18703055"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/6261"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/60313"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.relation.issn","0014-5793"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.subject.ddc","610"],["dc.subject.mesh","Angiogenesis Inhibitors"],["dc.subject.mesh","Apoptosis"],["dc.subject.mesh","Cells, Cultured"],["dc.subject.mesh","Choroidal Neovascularization"],["dc.subject.mesh","Coculture Techniques"],["dc.subject.mesh","Humans"],["dc.subject.mesh","Pigment Epithelium of Eye"],["dc.subject.mesh","Sirolimus"],["dc.subject.mesh","Vascular Endothelial Growth Factor A"],["dc.title","Rapamycin reduces VEGF expression in retinal pigment epithelium (RPE) and inhibits RPE-induced sprouting angiogenesis in vitro."],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","e0181766"],["dc.bibliographiccitation.issue","8"],["dc.bibliographiccitation.journal","PloS one"],["dc.bibliographiccitation.volume","12"],["dc.contributor.author","Callizo, Josep"],["dc.contributor.author","Feltgen, Nicolas"],["dc.contributor.author","Ammermann, Antje"],["dc.contributor.author","Ganser, Janina"],["dc.contributor.author","Bemme, Sebastian"],["dc.contributor.author","Bertelmann, Thomas"],["dc.contributor.author","Pfeiffer, Sebastian"],["dc.contributor.author","Duvinage, Andre"],["dc.contributor.author","Gröschel, Klaus"],["dc.contributor.author","Hoerauf, Hans"],["dc.contributor.author","Wachter, Rolf"],["dc.date.accessioned","2019-07-09T11:43:38Z"],["dc.date.available","2019-07-09T11:43:38Z"],["dc.date.issued","2017"],["dc.description.abstract","BACKGROUND: Patients with retinal vascular occlusion disease have an increased risk for ischemic stroke and share some risk factors with cerebrovascular disease. The purpose of this study was to analyze the prevalence of atrial fibrillation (AF) in subjects with retinal vascular occlusive disease and anterior ischemic optic neuropathy and to compare these data to an ischemic stroke group. METHODS: Prospective, observational single-center trial. Subjects with retinal artery occlusion (RAO), retinal vein occlusion (RVO) and anterior ischemic optic neuropathy (AION) were included. Patients with ischemic stroke (IS) from a previous observational trial were used as control. Investigation included 7-day Holter ECG, echocardiography, duplex ultrasonography of the carotid arteries, and 24-hour blood pressure monitoring. Further vascular risk factors were documented. RESULTS: During the 1-year study period, 101 patients were recruited. The control group with ischemic stroke consisted of 272 subjects. At inclusion, the prevalence of AF was 12% (RAO), 10.2% (RVO), 11.1% (NAION) and 15.8% (IS). The final prevalence after Holter ECG rose to 16% (RAO), 18.4% (RVO), 14.8% (NAION) and 26.5% (IS). No significant difference was measured between groups. CONCLUSIONS: We detected a similar prevalence of AF in all groups. RVO patients tended to exhibit a higher AF detection rate and lower number needed to screen than RAO and NAION. The detection of AF rose considerably via Holter ECG. As a consequence, we recommend prolonged ECG monitoring in patients with acute ophthalmic vascular diseases."],["dc.identifier.doi","10.1371/journal.pone.0181766"],["dc.identifier.pmid","28771491"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/14599"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/58930"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.relation.issn","1932-6203"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.subject.ddc","610"],["dc.title","Atrial fibrillation in retinal vascular occlusion disease and non-arteritic anterior ischemic optic neuropathy."],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]